CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2011-09-06): Pharmasset hep C drug shows promise in mid-stage trial

Drug & Device Development

Pharmasset hep C drug shows promise in mid-stage trial

Last Updated: 2011-09-06 19:10:02 -0400 (Reuters Health)

BANGALORE (Reuters) - Pharmasset Inc said its hepatitis C drug showed positive results in a mid-stage trial in patients who have not been previously treated for the infection.

In the mid-stage study, named PROTON, 98% of patients had no detectable virus in the blood 12 weeks after the treatment was completed.

Patients were given either 400 mg or 200 mg doses of the drug, PSI-7977, once daily for 12 weeks in combination with peginterferon alfa 2a and ribavirin, the current standard of care.

Patients will now be monitored to check for virus levels 24 weeks after treatment completion, which is the main goal of the study, the company said in a statement.

Slide Library
Abstract Library
CME Dinner Meeting
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.